BBOT
Bridgebio Oncology Therapeutics
$2.64
−$0.02 (−0.75%)Oct 26, 2026
Key metrics
The numbers that frame BBOT today
- Market cap
- $211.66M
- ROIC
- -106.7%
- Div yield
- 0%
- Debt / equity
- 0.0
- 52wk Low
- $2.60
- 52wk High
- $14.87
Growth
Revenue and earnings trend for BBOT
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about BBOT
Is Bridgebio Oncology Therapeutics a good buy?
No. Bridgebio Oncology Therapeutics has poor quality and poor momentum. Both signals point to a weaker setup. Growth looks poor. That could put pressure on the long-term business case. We think Bridgebio Oncology Therapeutics is selling at a very high price.
What is the market capitalization of BBOT?
Bridgebio Oncology Therapeutics's market capitalization is $211.66M.
What is the 52-week high for BBOT stock?
The 52-week high for Bridgebio Oncology Therapeutics is $14.87. The current close of $2.64 is 82.2% below that high.
What is the 52-week low for BBOT stock?
The 52-week low for Bridgebio Oncology Therapeutics is $2.60. The current close of $2.64 is 1.5% above that low.
Does BBOT stock pay dividends?
Bridgebio Oncology Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for BBOT?
Bridgebio Oncology Therapeutics's Debt / Equity ratio is 0.01.